CAS Registry Number is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
HTT is expressed in all cells, with the highest concentrations found in the brain and testes, and moderate amounts in the liver, heart, and lungs. Although its full range of functions is not yet understood, HTT interacts with proteins involved in transcription, cell signaling, and intracellular transport. Studies in genetically modified animals have shown that wild-type HTT is essential for embryonic development, as complete absence of the gene results in embryonic death. HTT also plays a protective role in mature neurons: it regulates the production of brain-derived neurotrophic factor, supports synaptic vesicular transport and synaptic transmission, controls neuronal gene transcription, and prevents programmed cell death by inhibiting apoptotic enzymes such as caspases. In contrast to these protective roles, the mutant form of the protein (mHTT) interferes with the ubiquitin-proteasome system, which promotes caspase activation, contributing to neurodegeneration. Increasing the expression of HTT can promote brain cell survival and ameliorate the effects of mHTT, whereas reducing it can exacerbate those effects. Accordingly, the disease is thought not to be caused by inadequate expression of HTT, but by a toxic gain-of-function of mHTT in the body. The mutant protein is expressed throughout the body and associated with abnormalities in peripheral tissues outside of the brain, which can include muscle atrophy, cardiac failure, impaired glucose tolerance, weight loss, osteoporosis, and testicular atrophy.
== Physiological immune surveillance == After supra-gingival oral hygiene cleaning, plaque biofilm will quickly develop at the gingival margin and will enter the gingival sulcus after some time. The junctional epithelium, which is at the base of the gingival sulcus, permits plaque bacteria and its toxin to enter the underlying gingival connective tissue via the large spaces between epithelial cells of the junctional epithelium. As a result, inflammation occurs. In clinical gingival health, homeostasis occurs because resident biofilm of plaque bacteria and the host defences (symbiosis) results in a dynamic equilibrium with oral hygiene practices such as brushing and flossing. Therefore, despite having clinical gingival health, a low level of inflammatory infiltrate, consisting of neutrophils, B Cell Lymphocytes and macrophages, is always present in the connective tissue underlying the junctional epithelium. Essentially, this means that histologically, there will always be an inflammatory reaction to bacteria from plaque. The constant low-level inflammatory reaction in the connective tissue underlying the junctional epithelium also results in the formation of the Gingival Crevicular Fluid (GCF). The Gingival Crevicular Fluid (GCF) is a serum like fluid that is formed from the post capillary venules of the Dentogingival Plexus which is a dense network of blood vessels within the gingival connective tissue that is sub-adjacent to the junctional epithelium. The Gingival Crevicular Fluid (GCF) is made up of various components of cells and blood.
This is echoed by Reynolds and Kravitz in their survey of the literature where they remarked: "the overall weight-control benefits of EPOC, for men and women, from participation in resistance exercise occur over a significant time period, since kilocalories are expended at a low rate in the individual post-exercise sessions." The EPOC effect clearly increases with the intensity of the exercise, and (at least in the case of aerobic exercise, perhaps also for anaerobic) the duration of the exercise. Studies comparing intermittent and continuous exercise consistently show a greater EPOC response for higher intensity, intermittent exercise.
Also, during the 1981 tour, veteran session drummer Andy Newmark stepped in briefly for Knudsen, who was then in rehab. And by the end of 1981, even Simmons had left the band. Now with no remaining original members and a "leader" in McDonald who was ready for a solo career, the group elected instead to disband after a rehearsal without Simmons, according to an interview with McDonald for Listen to the Music, the Doobie Brothers' official video history/documentary released in 1989. He went on to say that by that point they could not have gotten further away from the Doobies sound if they had tried. Simmons, already at work on his first solo album, Arcade, rejoined for a 1982 farewell tour on the condition that this truly would be the end of the Doobie Brothers. At their last concert at the Greek Theatre in Berkeley, California, on September 11, 1982, they were joined onstage by founding member Tom Johnston for what was presumed to be the final rendition of his staple, "China Grove". Former members Porter, Hossack and Hartman subsequently took the stage for an extended version of "Listen to the Music". Knudsen sang lead vocals while Johnston, Simmons and McFee traded licks on guitar. The live album Farewell Tour was released in 1983 and the Greek Theatre concert was released in 2011 as Live at the Greek Theatre 1982.
Hydrogen sulfide is about one-half as toxic as hydrogen cyanide, and intoxicates by the same mechanism (inhibition of the respiratory enzyme cytochrome oxidase), though hydrogen sulfide is less likely to cause sudden poisonings from small inhaled amounts (near its permissible exposure limit (PEL) of 20 ppm) because of its disagreeable odor. However, its presence in ambient air at concentration over 100–150 ppm quickly deadens the sense of smell, and a victim may breathe increasing quantities without noticing until severe symptoms cause death. Dissolved sulfide and hydrosulfide salts are toxic by the same mechanism.
Sources: en.wikipedia.org
Three buildings in the World Trade Center collapsed due to fire-induced structural failure. Although the South Tower was struck around seventeen minutes after the North Tower, the plane's impact zone was far lower, at a much faster speed, and into a corner, with the unevenly-balanced additional structural weight causing it to collapse first at 9:59 a.m., having burned for 56 minutes in the fire caused by the crash of United Airlines Flight 175 and the explosion of its fuel. The North Tower lasted just under 29 and a half minutes longer, before collapsing at 10:28 a.m., just under one hour and forty-two minutes after being struck by American Airlines Flight 11. When the North Tower collapsed, debris fell on the nearby 7 World Trade Center building (7 WTC), damaging the building and starting fires. These fires burned for nearly seven hours, compromising the building's structural integrity, and 7 WTC collapsed at 5:21 p.m. The west side of the Pentagon sustained significant damage. At 9:42 a.m., the Federal Aviation Administration (FAA) grounded all civilian aircraft within the continental U.S., and civilian aircraft already in flight were told to land immediately. All international civilian aircraft were either turned back or redirected to airports in Canada or Mexico, and were banned from landing on United States territory for three days. The attacks created widespread confusion among news organizations and air traffic controllers.
== Applications == Many derivatives of early metal metallocenes are active catalysts for olefin polymerization. Unlike traditional and still dominant heterogeneous Ziegler–Natta catalysts, metallocene catalysts are homogeneous. Early metal metallocene derivatives, e.g. Tebbe's reagent, Petasis reagent, and Schwartz's reagent are useful in specialized organic synthetic operations.
Increased appetite, weight gain, nausea, malaise, Increased risk of infection Cardiovascular events Dermatological effects including reddening of the face, bruising/skin discoloration, impaired wound healing, skin atrophy, skin rash, edema, and abnormal hair growth Hyperglycemia; patients with diabetes may need increased insulin or diabetic therapies Menstrual abnormalities Lower response to hormones, especially during stressful instances such as surgery or illness Change in electrolytes: rise in blood pressure, increased sodium and low potassium, leading to alkalosis Gastrointestinal system effects: swelling of the stomach lining, reversible increase in liver enzymes, and risk of stomach ulcers Muscular and skeletal abnormalities, such as muscle weakness/muscle loss, osteoporosis (see steroid-induced osteoporosis), long bone fractures, tendon rupture, and back fractures Neurological effects, including involuntary movements (convulsions), headaches, and vertigo Psychosocial behavioral and emotional disturbances with aggression being one of the most common cognitive symptoms, especially with oral use. Nasal septum perforation and bowel perforation (in some pathologic conditions). Discontinuing prednisolone after long-term or high-dose use can lead to adrenal insufficiency. Mania and hypomania are known possible side effects of prednisolone.
=== December === 1 December – Michael Russell steps down as chairman of the Scottish National Party as he bids to become chairman of the Scottish Land Commission. 5 December – The Scottish Prison Service issues new guidelines on transgender prisoners. Trans women who have hurt or threatened women or girls will not be sent to a female prison unless there are "exceptional" circumstances. 6 December – The Court of Session in Edinburgh rejects a bid by the Scottish Government to prevent the publication of details of an inquiry into whether former First Minister Nicola Sturgeon broke the ministerial code over a meeting with Alex Salmond's aide in the aftermath of allegations against Salmon in 2021. 7 December – Conservative councillor Wendy Agnew resigns as chair of Aberdeenshire Council's Kincardine and Mearns area committee following comments made about gypsies during a council meeting in November. Agnew is also being investigated by the Ethical Standards Commissioner following a complaint about the comments. 8 December – The Court of Session in Edinburgh rules that the UK government acted lawfully by blocking the Gender Recognition Reform (Scotland) Bill from becoming law, and rejects the Scottish Government's appeal against the decision. 9 December – An earthquake measuring 2.1 magnitude is felt in parts of the Scottish Highlands.
== Preparation == An aqueous solution of sodium silicate is acidified to produce a gelatinous precipitate that is washed, then dehydrated to produce colorless silica gel. When a visible indication of the moisture content of the silica gel is required, ammonium tetrachlorocobaltate(II) (NH4)2[CoCl4] or cobalt(II) chloride CoCl2 is added. This will cause the gel to be blue when dry and pink when hydrated. Due to a link between the cobalt chloride and cancer, it has been forbidden in Europe for use in silica gel. An alternative indicator is methyl violet, which is orange when dry and green when hydrated.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.